Form 4 for ABT Abbott Laboratories
Accepted 2024-01-31 00:00:00 ET · period of report 2024-01-29 · accession 0001415889-24-002080 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-31 | 2024-01-29 | ABT | Wainer Andrea F | EVP | M - OptEx | $50.80 | +42.5K | 82.5K | +106% | +$2.16M |
| DM | 2024-01-31 | 2024-01-29 | ABT | Wainer Andrea F | EVP | S - Sale+OE | $112.50 | -42.5K | 65.0K | -40% | -$4.78M |
| DM | 2024-01-31 | 2024-01-29 | ABT | Wainer Andrea F | EVP | M - OptEx | $0.00 | -42.5K | 13.3K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2024-01-29 | M | A | 25,000 | $44.40 | 90,027 | D | — | — | |
| 2 | Common | Common shares without par value | 2024-01-29 | S | D | 25,000 | $112.50 | 65,027 | D | — | — | |
| 3 | Common | Common shares without par value | 2024-01-29 | M | A | 17,500 | $59.94 | 82,527 | D | — | — | |
| 4 | Common | Common shares without par value | 2024-01-29 | S | D | 17,500 | $112.50 | 65,027 | D | — | — | |
| 5 | Derivative | Option (right to buy) | 2024-01-29 | M | D | 17,500 | $0.00 | 46,949 | D | $59.94 · 2021-02-16 to 2028-02-15 | 17,500 Common Shares | (F2) Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| 6 | Derivative | Option (right to buy) | 2024-01-29 | M | D | 25,000 | $0.00 | 13,271 | D | $44.40 · 2020-02-17 to 2027-02-16 | 25,000 Common Shares | (F1) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |